CenterBook Partners LP Invests $1.20 Million in Sionna Therapeutics, Inc. (NASDAQ:SION)

Key Points

• CenterBook Partners LP invested approximately $1,195,000 in Sionna Therapeutics by acquiring 114,284 shares, giving them about 0.26% ownership of the company.
• Recently, several institutional investors, including Jennison Associates LLC and TD Asset Management Inc, also established new stakes in Sionna Therapeutics, reflecting growing interest in the company.
• Sionna Therapeutics reported a quarterly loss of ($0.62) EPS, underperforming against analysts' estimates of ($0.45), and has seen its stock price fluctuate between a 12-month low of $7.26 and a high of $25.19.

CenterBook Partners LP bought a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 114,284 shares of the company's stock, valued at approximately $1,195,000. CenterBook Partners LP owned approximately 0.26% of Sionna Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in SION. Jennison Associates LLC purchased a new stake in shares of Sionna Therapeutics in the first quarter worth $8,995,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Sionna Therapeutics in the first quarter worth $676,000. Finally, TD Asset Management Inc purchased a new stake in shares of Sionna Therapeutics in the first quarter worth $579,000.

Sionna Therapeutics Trading Up 3.7%

Shares of NASDAQ:SION traded up $0.75 on Tuesday, reaching $20.78. 148,409 shares of the company traded hands, compared to its average volume of 187,432. The business has a 50-day simple moving average of $17.66. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $25.19.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.27.

Insider Buying and Selling at Sionna Therapeutics

In related news, major shareholder Tpg Gp A, Llc acquired 60,000 shares of the stock in a transaction on Friday, June 27th. The stock was acquired at an average cost of $15.84 per share, for a total transaction of $950,400.00. Following the completion of the acquisition, the insider directly owned 6,744,962 shares of the company's stock, valued at approximately $106,840,198.08. This represents a 0.90% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.90% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen cut Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.

Sionna Therapeutics Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.